ZLAB News and Press, Zai Lab Limited From 07/13/22

Zai Lab ( NASDAQ: ZLAB ) on Wednesday said China's drug regulator had accepted the company's biologics license application (BLA) for efgartigimod alfa injection for the treatment of generalized myasthenia gravis (gMG). Myasthenia gravis is a disorder characterized by w...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that China’s National Medical Products Administration (NMP...

Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion PR Newswire SHANGHAI , July 10, 2022 /PRNewswire/ -- Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion , including USD Fund VIII a...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...

Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones. Shanghai Zai Lab has changed its Hong Kong listing from secondar...

–   First company to Convert from Secondary to Primary Listing Status in Hong Kong –   Our dual Primary Listing on the Nasdaq and Hong Kong Stock Exchange provides greater access for investors SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass...

TAL Education Group (NYSE:TAL) and Mercury Fintech (NASDAQ:MFH) were added to a list of companies that face possible delisting from U.S. exchanges,  the Securities and Exchange Commission said on Friday. The two companies were added to the Holding Foreign Companies Accountable Act, or HF...

Applied Therapeutics ( APLT ) -22% on pricing $30M equity offering . Xenon Pharmaceuticals ( XENE ) -13% on pricing $250M equity offering . Clovis Oncology ( CLVS ) -10% Zai Lab ( ZLAB ) -9% on conversion of secondary listing in Ho...

China's National Medical Products Administration granted two breakthrough therapy designations to Zai Lab's (NASDAQ:ZLAB) repotrectinib to treat certain patients with non-small cell lung cancer (NSCLC). The designation for the drug is to treat patients with ROS1-posit...

-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior chemotherapy -- Potential best-in-class therapy for ROS1-positive metastatic NS...